{"result": "(\"entity\"<|>QSYMIA<|>ORGANIZATION<|>Qsymia is a combination medication used for weight loss, containing phentermine and topiramate, aimed at enhancing weight loss effects while minimizing side effects.)\n##\n(\"entity\"<|>ORLISTAT<|>ORGANIZATION<|>Orlistat, marketed as Xenical in Europe, is a medication that inhibits fat absorption from the diet, contributing to weight loss.)\n##\n(\"entity\"<|>EQUIP<|>EVENT<|>EQUIP is a randomized controlled trial studying the effects of controlled-release phentermine and topiramate in severely obese adults.)\n##\n(\"entity\"<|>CONQUER<|>EVENT<|>The CONQUER study examines the effects of low-dose, controlled-release phentermine plus topiramate on weight and associated comorbidities in overweight and obese adults.)\n##\n(\"entity\"<|>XENDOS<|>EVENT<|>XENDOS is a randomized double-blind study assessing the prevention of diabetes in obese subjects using Xenical.)\n##\n(\"relationship\"<|>QSYMIA<|>ORLISTAT<|>Both Qsymia and Orlistat are medications used for weight loss, targeting obesity through different mechanisms of action.<|>7)\n##\n(\"relationship\"<|>EQUIP<|>QSYMIA<|>The EQUIP study evaluates the effectiveness of Qsymia in severely obese adults, linking the medication to clinical research.<|>8)\n##\n(\"relationship\"<|>CONQUER<|>QSYMIA<|>The CONQUER study investigates the effects of Qsymia on weight loss and related health issues, establishing a direct connection between the medication and its clinical outcomes.<|>8)\n##\n(\"relationship\"<|>XENDOS<|>ORLISTAT<|>XENDOS is a study that assesses the effectiveness of Orlistat in preventing diabetes in obese patients, linking the medication to clinical research outcomes.<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: por la                           (agente orexígeno), inhibe también la anhidrasa carbó-\n---\n                                                                  Tema 8.    Tratamiento farmacológico de la obesidad               135\n\n\n\nnica y aumenta la actividad del ácido gamma-amino-                  hiperclorémica, alteraciones hepáticas o renales. Em-\nbutírico (GABA).                                                    peoramiento       cognitivo     si se   emplea     concomitante-\n   La idea de esta combinación es emplear dosis muy                 mente con alcohol o antidepresivos. Puede producir\ninferiores a las habituales con la finalidad de potenciar           pérdidas menstruales a lo largo del ciclo en pacientes\nsus efectos y disminuir los potenciales efectos secunda-            que toman anticonceptivos, por alteraciones en el me-\nrios. Así, los ensayos con Qsymia® se han realizado con             tabolismo de estrógenos y progestágenos10.\ndosis bajas con 3,75 mg de fentermina y 23 mg de\ntopiramato (3,75/23 mg), una dosis media de 7,5/46                  3.   Fármacos comercializados en Europa\nmg y una dosis alta de 15/92 mg, indicada en aquellos\npacientes que no alcancen una meta de pérdida de                    3.1.   Orlistat\npeso con las dosis inferiores.                                        Orlistat (Xenical®) está comercializado en Europa\n   Se han realizado tres estudios aleatorizados doble-              desde 1998. Su mecanismo de acción se relaciona con\nciego con placebo, en fase III, con diferentes dosis de             la inhibición de la absorción de las grasas de la dieta,\nesta combinación: EQUIP (Controlled-Release Phenter-                en una proporción del 30% de la ingesta, al inhibir par-\nmine/Topiramate in Severely Obese Adults: A Rando-\nmized Controlled Trial11, The CONQUER (Effects of                   cialmente la acción de las lipasas gástrica y pancreáti-\n                              )                                     ca. Esta acción es causa directa de sus conocidos efec-\nLow-Dose, Controlled-Release, Phentermine Plus Topi-                tos secundarios (flatulencia, aumento de deposiciones,\nramate Combination on Weight and Associated Co-                     heces grasientas, manchas oleosas, etc.), presentes en\nmorbidities in Overweight and Obese Adults)12, y su                 el 15-20% de los pacientes, pero que no han sido mo-\nextensión a dos años (estudio SEQUEL)13. Los cambios                tivo habitual de abandono del tratamiento por parte\npromedios de pérdida de peso oscilaron de –1,2 a                    de los pacientes. El tratamiento con orlistat, 120 mg\n–2,5% para placebo; –7,8 a –9,3% para la dosis media                3 veces/día, contribuye a una pérdida de peso en un\nde 7,5/46 mg y entre el 10,5 al 12,1% para la dosis alta            2,9% superior al placebo14, contribuyendo a disminuir\nde 15/92 mg de esta combinación. El porcentaje de                   las comorbilidades metabólicas asociadas a la obesi-\nsujetos que pierden ≥ 5% del peso corporal oscila entre             dad, mientras que con la dosis de 60 mg/3 veces al día\nel 17-21% para placebo, 62% para la dosis media y                   (Alli®) se pierde 2,5 kg más que con placebo. Entre el\nentre el 67-70% para la dosis más alta de la asociación             35-73% de los sujetos perdieron ≥ 5% del peso inicial,\nFEN/TPM. En los resultados de metanálisis, la tasa glo-             según diferentes estudios, lo que supone una OR de\nbal de pacientes que alcanzan una pérdida de peso                   2,70 (IC95 2,34-3,09)9. En el estudio XENDOS (Xenical\n≥\n(IC 95% 6,63-12,85)9 5% respecto a placebo supone una OR de 9,22    in the prevention of diabetes in obese subjects), un es-\n   Los efectos secundarios son los mismos que pueden                tudio aleatorizado doble-ciego frente a placebo reali-\npresentarse por separado: sequedad de boca, estreñi-                zado en 3305 pacientes con obesos no diabéticos, al\n                                                                    finalizar los 4 años de seguimiento, con una diferencia\nmiento, parestesias, somnolencia, ansiedad, alteracio-              de tan solo 2,7 kg frente a placebo, fue suficiente para\nnes de la memoria, etc. que suelen disminuir con el                 reducir el desarrollo de diabetes tipo 2 en un 37,3% en\npaso del tiempo. La tasa de abandonos es solo del 31%               aquellos pacientes que tenían predi\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}